2026 ICD-10-CM Diagnosis Code T46.8X5SAdverse effect of antivaricose drugs, including sclerosing agents, sequela
T46.8X5S is a billable ICD-10-CM diagnosis code for adverse effect of antivaricose drugs, including sclerosing agents, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. Coders also document this condition as antivaricose agent adverse reaction. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T46.8X5S.
Present on Admission (POA)Billing
T46.8X5S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Antivaricose agent adverse reaction
- Ethanolamine adverse reaction
- Sodium tetradecyl sulfate adverse reaction
Coding GuidelinesGuidance
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of agents primarily affecting the cardiovascular system (T46). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Polidocanol
an alkyl polyglycol ether of lauryl alcohol, chemically defined as an alcohol ethoxylate having an average alkyl chain of 12–14 carbon atoms, and an ethylene oxide chain of 9 ethylene oxide units. it is used as a detergent, and medically as a local anesthetic, and as a sclerosing agent for the treatment of esophageal and gastric varices and varicose veins.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
| Substance | Accidental | Self-harm | Assault | Undetermined | Adverse Effect | Underdosing |
|---|---|---|---|---|---|---|
| Antivaricose drug | T46.8X1 | T46.8X2 | T46.8X3 | T46.8X4 | T46.8X5 | T46.8X6 |
| Ethanolamine oleate | T46.8X1 | T46.8X2 | T46.8X3 | T46.8X4 | T46.8X5 | T46.8X6 |
| Monoethanolamine | T46.8X1 | T46.8X2 | T46.8X3 | T46.8X4 | T46.8X5 | T46.8X6 |
| Monoethanolamine::oleate | T46.8X1 | T46.8X2 | T46.8X3 | T46.8X4 | T46.8X5 | T46.8X6 |
| Polidocanol | T46.8X1 | T46.8X2 | T46.8X3 | T46.8X4 | T46.8X5 | T46.8X6 |
| Sclerosing agent | T46.8X1 | T46.8X2 | T46.8X3 | T46.8X4 | T46.8X5 | T46.8X6 |
| Sotradecol | T46.8X1 | T46.8X2 | T46.8X3 | T46.8X4 | T46.8X5 | T46.8X6 |
| Varicose reduction drug | T46.8X1 | T46.8X2 | T46.8X3 | T46.8X4 | T46.8X5 | T46.8X6 |
| Venous sclerosing drug NEC | T46.8X1 | T46.8X2 | T46.8X3 | T46.8X4 | T46.8X5 | T46.8X6 |
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T46.8X5S to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T46.8X5SOverview
Is T46.8X5S a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of antivaricose drugs, including sclerosing agents, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character S in T46.8X5S mean?
The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of antivaricose drugs, including sclerosing agents itself has resolved, not the original event.
What MS-DRG does T46.8X5S group to?
On inpatient claims, adverse effect of antivaricose drugs, including sclerosing agents, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.
Can T46.8X5S be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of antivaricose drugs, including sclerosing agents, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
Is T46.8X5S exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of antivaricose drugs, including sclerosing agents, sequela on inpatient claims.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
